<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014402</article-id><article-id pub-id-type="pmcid-ver">PMC2014402.1</article-id><article-id pub-id-type="pmcaid">2014402</article-id><article-id pub-id-type="pmcaiid">2014402</article-id><article-id pub-id-type="pmid">10930964</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00231.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Population Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Anderson</surname><given-names initials="BJ">Brian J</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Woollard</surname><given-names initials="GA">Gerald A</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holford</surname><given-names initials="NHG">Nicholas H G</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><aff id="au1"><label>1</label><institution>Auckland Children's Hospital</institution><addr-line>Auckland, NZ</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Clinical Chemistry, Auckland Public Hospital</institution><addr-line>NZ</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Pharmacology and Clinical Pharmacology, University of Auckland School of Medicine</institution><addr-line>NZ</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Dr Brian Anderson, PICU, Auckland Children's Hospital, New Zealand. Ph 64&#8211;9-3074903, Fax: 64&#8211;9-3078986, E-mail: <email>briana@ahsl.co.nz</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2000</year></pub-date><volume>50</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">151551</issue-id><fpage>125</fpage><lpage>134</lpage><history><date date-type="received"><day>11</day><month>10</month><year>1999</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:33:58.600"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0125.pdf"/><abstract><sec><title>Aims</title><p>The aims of this study were to describe paracetamol pharmacokinetics in neonates and infants.</p></sec><sec sec-type="methods"><title>Methods</title><p>Infants in their first 3 months of life (<italic>n</italic> = 30) were randomised to sequentially receive one of three paracetamol formulations (dose 30&#8211;40 mg kg<sup>&#8722;1</sup>) over a 2 day period. The formulations were (a) elixir, (b) glycogelatin capsule suppository and (c) triglyceride base suppository. Approximately six blood samples were taken after each dose over the subsequent 10&#8211;16 h. Data were analysed using a nonlinear mixed effect model. These neonatal and infant data were then included with data from four published studies of paracetamol pharmacokinetics (<italic>n</italic> = 221) and age-related pharmacokinetic changes investigated.</p></sec><sec><title>Results</title><p>Population pharmacokinetic parameter estimates and their coefficients of variation (CV%) for a one compartment model with first order input, lag time and first order elimination were volume of distribution 69.9 (18%) l and clearance 13.0 (41%) l h<sup>&#8722;1</sup> (standardized to a 70 kg person). The volume of distribution decreased exponentially with a half-life of 1.9 days from 120 l 70 kg<sup>&#8722;1</sup> at birth to 69.9 l 70 kg<sup>&#8722;1</sup> by 14 days. Clearance increased from birth (4.9 l h<sup>&#8722;1</sup> 70 kg<sup>&#8722;1</sup>) with a half-life of 3.25 months to reach 12.4 l h<sup>&#8722;1</sup> 70 kg<sup>&#8722;1</sup> by 12 months. The absorption half-life (<italic>t</italic><sub>abs</sub>) for the oral preparation was 0.13 (154%) h with a lag time (<italic>t</italic><sub>lag</sub>) of 0.39 h (31%). Absorption parameters for the triglyceride base and capsule suppositories were <italic>t</italic><sub>abs</sub> 1.34 (90%) h, <italic>t</italic><sub>lag</sub> 0.14 h (31%) and <italic>t</italic><sub>abs</sub> 0.65 (63%) h, <italic>t</italic><sub>lag</sub> 0.54 h (31%), respectively. The <italic>t</italic><sub>abs</sub> for elixir and capsule suppository in children under 3 months were 3.68 and 1.51 times greater than children over 3 months. The relative bioavailability of rectal formulations compared with elixir were 0.67 (30%) and 0.61 (23%) for the triglyceride base and capsule suppositories, respectively.</p></sec><sec><title>Conclusions</title><p>Total body clearance of paracetamol at birth is 62% and volume of distribution 174% that of older children. A target concentration above 10 mg l<sup>&#8722;1</sup> in approximately 50% subjects can be achieved by a dose from 45 mg kg<sup>&#8722;1</sup> day<sup>&#8722;1</sup> at birth and up to 90 mg kg<sup>&#8722;1</sup> day<sup>&#8722;1</sup> in 5-year-old children. A reduced dose of 75 mg kg<sup>&#8722;1</sup> day<sup>&#8722;1</sup> in an 8-year-old child is sufficient because clearance is a nonlinear function of weight.</p></sec></abstract><kwd-group><kwd>allometry</kwd><kwd>comparative bioavailability</kwd><kwd>NONMEM</kwd><kwd>paediatric</kwd><kwd>paracetamol</kwd><kwd>population pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>